Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
ABIVAX Société Anonyme stock logo
ABVX
ABIVAX Société Anonyme
$5.72
+0.5%
$6.28
$4.77
$14.71
$359.94M0.29140,681 shs290,200 shs
Atossa Therapeutics, Inc. stock logo
ATOS
Atossa Therapeutics
$0.82
+0.8%
$0.75
$0.55
$1.66
$105.92M1.01778,931 shs1,754 shs
Precigen, Inc. stock logo
PGEN
Precigen
$1.39
+1.1%
$1.43
$0.65
$2.17
$406.17M1.821.33 million shs100 shs
Sage Therapeutics, Inc. stock logo
SAGE
Sage Therapeutics
$6.52
+0.0%
$7.23
$4.62
$13.47
$412.67M0.21.19 million shs673,816 shs
Ten Starter Stocks For Beginners to Buy Now Cover

Just getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
ABIVAX Société Anonyme stock logo
ABVX
ABIVAX Société Anonyme
-0.18%-2.41%-21.76%-26.14%-58.84%
Atossa Therapeutics, Inc. stock logo
ATOS
Atossa Therapeutics
-3.19%-6.60%+9.48%+9.15%-42.73%
Precigen, Inc. stock logo
PGEN
Precigen
-2.84%+3.79%-11.61%-21.71%+0.37%
Sage Therapeutics, Inc. stock logo
SAGE
Sage Therapeutics
-0.61%-4.71%-16.60%-9.87%-45.68%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
ABIVAX Société Anonyme stock logo
ABVX
ABIVAX Société Anonyme
2.5227 of 5 stars
3.54.00.00.02.20.80.6
Atossa Therapeutics, Inc. stock logo
ATOS
Atossa Therapeutics
1.573 of 5 stars
3.50.00.00.03.21.70.0
Precigen, Inc. stock logo
PGEN
Precigen
3.659 of 5 stars
3.50.00.04.72.51.70.6
Sage Therapeutics, Inc. stock logo
SAGE
Sage Therapeutics
3.769 of 5 stars
3.01.00.04.02.91.71.3
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
ABIVAX Société Anonyme stock logo
ABVX
ABIVAX Société Anonyme
3.00
Buy$31.00441.96% Upside
Atossa Therapeutics, Inc. stock logo
ATOS
Atossa Therapeutics
3.00
Buy$7.13768.90% Upside
Precigen, Inc. stock logo
PGEN
Precigen
3.00
Buy$7.00405.42% Upside
Sage Therapeutics, Inc. stock logo
SAGE
Sage Therapeutics
2.06
Hold$8.8735.97% Upside

Current Analyst Ratings Breakdown

Latest ATOS, ABVX, SAGE, and PGEN Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
5/15/2025
Precigen, Inc. stock logo
PGEN
Precigen
Cantor Fitzgerald
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOverweight ➝ Overweight
4/30/2025
ABIVAX Société Anonyme stock logo
ABVX
ABIVAX Société Anonyme
JMP Securities
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingMarket Outperform ➝ Market Outperform$33.00 ➝ $33.00
4/25/2025
Sage Therapeutics, Inc. stock logo
SAGE
Sage Therapeutics
Needham & Company LLC
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingHold ➝ Hold
4/21/2025
Atossa Therapeutics, Inc. stock logo
ATOS
Atossa Therapeutics
Ascendiant Capital Markets
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetBuy ➝ Buy$7.00 ➝ $7.25
3/26/2025
Atossa Therapeutics, Inc. stock logo
ATOS
Atossa Therapeutics
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$7.00 ➝ $7.00
3/20/2025
ABIVAX Société Anonyme stock logo
ABVX
ABIVAX Société Anonyme
Morgan Stanley
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingEqual Weight$12.00
3/20/2025
Precigen, Inc. stock logo
PGEN
Precigen
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$6.00 ➝ $6.00
3/12/2025
Atossa Therapeutics, Inc. stock logo
ATOS
Atossa Therapeutics
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$7.00 ➝ $7.00
3/11/2025
Sage Therapeutics, Inc. stock logo
SAGE
Sage Therapeutics
Bank of America
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageUnderperform$5.00
(Data available from 5/29/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
ABIVAX Société Anonyme stock logo
ABVX
ABIVAX Société Anonyme
N/AN/AN/AN/A$3.37 per shareN/A
Atossa Therapeutics, Inc. stock logo
ATOS
Atossa Therapeutics
N/AN/AN/AN/A$0.73 per shareN/A
Precigen, Inc. stock logo
PGEN
Precigen
$4.20M97.32N/AN/A$0.48 per share2.89
Sage Therapeutics, Inc. stock logo
SAGE
Sage Therapeutics
$47.40M8.61N/AN/A$7.56 per share0.86
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
ABIVAX Société Anonyme stock logo
ABVX
ABIVAX Société Anonyme
-$159.90MN/A0.00N/AN/AN/AN/AN/A6/2/2025 (Estimated)
Atossa Therapeutics, Inc. stock logo
ATOS
Atossa Therapeutics
-$30.09M-$0.21N/AN/AN/AN/A-35.74%-33.51%8/11/2025 (Estimated)
Precigen, Inc. stock logo
PGEN
Precigen
-$95.90M-$0.56N/AN/AN/A-3,521.68%-123.06%-87.33%8/13/2025 (Estimated)
Sage Therapeutics, Inc. stock logo
SAGE
Sage Therapeutics
-$400.67M-$5.80N/AN/AN/A-971.50%-68.18%-60.84%7/30/2025 (Estimated)

Latest ATOS, ABVX, SAGE, and PGEN Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
6/2/2025N/A
ABIVAX Société Anonyme stock logo
ABVX
ABIVAX Société Anonyme
-$1.5884N/AN/AN/A$3.11 millionN/A
5/14/2025Q1 2025
Precigen, Inc. stock logo
PGEN
Precigen
-$0.08-$0.07+$0.01-$0.18$0.50 million$1.34 million
5/13/2025Q1 2025
Atossa Therapeutics, Inc. stock logo
ATOS
Atossa Therapeutics
-$0.06-$0.05+$0.01-$0.05N/AN/A
4/29/2025Q1 2025
Sage Therapeutics, Inc. stock logo
SAGE
Sage Therapeutics
-$0.99-$1.01-$0.02-$1.01$14.12 million$14.06 million
3/25/2025Q4 2024
Atossa Therapeutics, Inc. stock logo
ATOS
Atossa Therapeutics
-$0.0633-$0.05+$0.0133-$0.05N/AN/A
3/19/2025Q4 2024
Precigen, Inc. stock logo
PGEN
Precigen
-$0.06-$0.04+$0.02-$0.06$1.30 million$1.19 million
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
ABIVAX Société Anonyme stock logo
ABVX
ABIVAX Société Anonyme
N/AN/AN/AN/AN/A
Atossa Therapeutics, Inc. stock logo
ATOS
Atossa Therapeutics
N/AN/AN/AN/AN/A
Precigen, Inc. stock logo
PGEN
Precigen
N/AN/AN/AN/AN/A
Sage Therapeutics, Inc. stock logo
SAGE
Sage Therapeutics
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
ABIVAX Société Anonyme stock logo
ABVX
ABIVAX Société Anonyme
0.48
3.04
N/A
Atossa Therapeutics, Inc. stock logo
ATOS
Atossa Therapeutics
N/A
13.30
13.30
Precigen, Inc. stock logo
PGEN
Precigen
N/A
1.63
1.63
Sage Therapeutics, Inc. stock logo
SAGE
Sage Therapeutics
N/A
7.42
7.42

Institutional Ownership

CompanyInstitutional Ownership
ABIVAX Société Anonyme stock logo
ABVX
ABIVAX Société Anonyme
47.91%
Atossa Therapeutics, Inc. stock logo
ATOS
Atossa Therapeutics
12.74%
Precigen, Inc. stock logo
PGEN
Precigen
33.51%
Sage Therapeutics, Inc. stock logo
SAGE
Sage Therapeutics
99.22%

Insider Ownership

CompanyInsider Ownership
ABIVAX Société Anonyme stock logo
ABVX
ABIVAX Société Anonyme
N/A
Atossa Therapeutics, Inc. stock logo
ATOS
Atossa Therapeutics
8.70%
Precigen, Inc. stock logo
PGEN
Precigen
44.90%
Sage Therapeutics, Inc. stock logo
SAGE
Sage Therapeutics
5.50%
CompanyEmployeesShares OutstandingFree FloatOptionable
ABIVAX Société Anonyme stock logo
ABVX
ABIVAX Société Anonyme
6163.44 millionN/ANot Optionable
Atossa Therapeutics, Inc. stock logo
ATOS
Atossa Therapeutics
8129.17 million116.24 millionOptionable
Precigen, Inc. stock logo
PGEN
Precigen
190295.18 million161.37 millionOptionable
Sage Therapeutics, Inc. stock logo
SAGE
Sage Therapeutics
69062.62 million58.10 millionOptionable

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

ABIVAX Société Anonyme stock logo

ABIVAX Société Anonyme NASDAQ:ABVX

$5.73 +0.04 (+0.74%)
As of 09:42 AM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

ABIVAX Société Anonyme, a clinical-stage biotechnology company, focuses on developing therapeutics that harness the body's natural regulatory mechanisms to stablize the immune response in patients with chronic inflammatory diseases. The company is evaluating its lead drug candidate, obefazimod, in Phase 3 clinical trials for the treatment of moderately to severely active ulcerative colitis in adults. ABIVAX Société Anonyme was incorporated in 2013 and is headquartered in Paris, France.

Atossa Therapeutics stock logo

Atossa Therapeutics NASDAQ:ATOS

$0.82 +0.01 (+0.84%)
As of 09:40 AM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

Atossa Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops medicines in the areas of unmet medical need in oncology for women breast cancer and other conditions in the United States. The company's lead drug candidate is oral (Z)-endoxifen, an active metabolite of tamoxifen, which is in Phase II clinical trials to treat and prevent breast cancer. It also develops immunotherapy/chimeric antigen receptor therapy programs. The company was formerly known as Atossa Genetics Inc. and changed its name to Atossa Therapeutics, Inc. in January 2020. Atossa Therapeutics, Inc. was founded in 2008 and is headquartered in Seattle, Washington.

Precigen stock logo

Precigen NASDAQ:PGEN

$1.38 +0.02 (+1.09%)
As of 09:41 AM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

Precigen, Inc. operates as a discovery and clinical-stage biopharmaceutical company that develops gene and cell therapies using precision technology to target diseases in therapeutic areas of immuno-oncology, autoimmune disorders, and infectious diseases. It operates through two segments, Biopharmaceuticals and Exemplar. The company offers therapeutic platforms consisting of UltraCAR-T to provide chimeric antigen receptor T cell therapies for cancer patients; AdenoVerse immunotherapy, which utilizes a library of proprietary adenovectors for gene delivery of therapeutic effectors, immunomodulators, and vaccine antigen; and ActoBiotics for specific disease modification. It also develops programs based on the UltraCAR-T platform, including PRGN-3005 in Phase 1b clinical trial to treat advanced ovarian, fallopian tube, or primary peritoneal cancer; PRGN-3006 in Phase 1b trial for patients with relapsed or refractory acute myeloid leukemia and high-risk myelodysplastic syndromes; and PRGN-3007 in Phase 1/1b trial for the treatment of advanced receptor tyrosine kinase-like orphan receptor 1-positive, hematologic, and solid tumors. In addition, the company is developing programs based on the AdenoVerse immunotherapy platform comprising PRGN-2009 in Phase 2 trial for patients with HPV-associated cancer; and PRGN-2012 in Phase ½ trial to treat recurrent respiratory papillomatosis, as well as AG019, which is based on the ActoBiotics platform and in Phase 1b/2a trial, to treat type 1 diabetes mellitus. Further, it provides UltraPorator, a proprietary electroporation device; and develops research models and services for healthcare research applications. The company was formerly known as Intrexon Corporation and changed its name to Precigen, Inc. in February 2020. Precigen, Inc. was founded in 1998 and is headquartered in Germantown, Maryland.

Sage Therapeutics stock logo

Sage Therapeutics NASDAQ:SAGE

$6.52 +0.00 (+0.02%)
As of 09:42 AM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

Sage Therapeutics, Inc., a biopharmaceutical company, develops and commercializes brain health medicines. Its product candidates include ZULRESSO, a CIV injection for the treatment of postpartum depression (PPD) in adults; and ZURZUVAE, a neuroactive steroid, a positive allosteric modulator of GABAA receptors, targeting both synaptic and extrasynaptic GABAA receptors, for the treatment of postpartum depression. Its product pipeline also comprises SAGE-324, a compound that is in Phase II clinical trial to treat essential tremors, as well as has completed Phase I clinical trial for epilepsy and Parkinson's diseases; and SAGE-718, an oxysterol-based positive allosteric modulator of the NMDA receptor, which is in Phase II clinical trial for the treatment of depression, Huntington's disease, Parkinson's diseases, Alzheimer's disease, attention deficit hyperactivity disorder, schizophrenia, and neuropathic pain. The company has a strategic collaboration with Shionogi & Co., Ltd. for the development and commercialization of zuranolone in Japan, Taiwan, and South Korea; and a collaboration and license agreement with Biogen MA Inc. to jointly develop and commercialize SAGE-217 and SAGE-324 products. The company was formerly known as Sterogen Biopharma, Inc. and changed its name to Sage Therapeutics, Inc. in September 2011. Sage Therapeutics, Inc. was incorporated in 2010 and is headquartered in Cambridge, Massachusetts.